dc.contributor.author | Mateo-Casas, M | |
dc.contributor.author | Reyes, S | |
dc.contributor.author | De Trane, S | |
dc.contributor.author | Edwards, F | |
dc.contributor.author | Espasandin, M | |
dc.contributor.author | Anjorin, G | |
dc.contributor.author | Baker, D | |
dc.contributor.author | Schmierer, K | |
dc.contributor.author | Giovannoni, G | |
dc.date.accessioned | 2020-11-12T16:46:06Z | |
dc.date.available | 2020-09-30 | |
dc.date.available | 2020-11-12T16:46:06Z | |
dc.date.issued | 2020-10-09 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/68267 | |
dc.description.abstract | Objective: To describe a fatal case of influenza A pneumonia in a patient with severe lymphopenia after receiving subcutaneous cladribine to treat her multiple sclerosis (MS). Methods: Case report. Results: A 53-year-old woman developed fatal influenza pneumonia associated with grade 4 lymphopenia two months after receiving a total dose of 60mg subcutaneous cladribine. Despite treatment with oseltamivir, her condition deteriorated and the patient passed away after developing respiratory failure. Conclusion: Cladribine-related lymphopenia is usually mild to moderate, however severe lymphopenia may occur. People with MS, especially those who are immunosuppressed, should be offered the inactivated influenza vaccine annually. | en_US |
dc.format.extent | 100279 - ? | |
dc.language | eng | |
dc.relation.ispartof | eNeurologicalSci | |
dc.rights | CC BY-NC-ND license | |
dc.rights | Attribution-NonCommercial-NoDerivs | * |
dc.rights.uri | http://creativecommons.org/licenses/BY-NC-ND/4.0/ | * |
dc.subject | Adverse event | en_US |
dc.subject | Cladribine | en_US |
dc.subject | Disease-modifying treatment | en_US |
dc.subject | Influenza A virus | en_US |
dc.subject | Lymphopenia | en_US |
dc.subject | Multiple Sclerosis | en_US |
dc.title | Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not? | en_US |
dc.type | Article | en_US |
dc.rights.holder | © 2020 Published by Elsevier B.V. | |
dc.identifier.doi | 10.1016/j.ensci.2020.100279 | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33163633 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
pubs.volume | 21 | en_US |
dcterms.dateAccepted | 2020-09-30 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |